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Abstract 
Introduction. Vascular endothelial growth factor (VEGF) is known to influence testis function. Transforming 
growth factor alpha (TGF-a) is expressed in the postnatal testis, and has been demonstrated to stimulate testis 
development. Systemic diseases such as chronic renal failure (CRF) interfere with hypothalamic-pituitary-go-
nadal axis, which may cause defective steroidogenesis and gonadal functions. The aim of this study was to inve-
stigate the expression and localization of VEGF and TGF-a in testicular tissues of experimental CRF model. 
Material and methods. Experimental CRF was induced in rats by the resection of more than 85% of 
renal mass. The expression of VEGF and TGF-a in testicular tissues were assessed by immunohistochemistry 
on paraffin sections of control, CRF-nondialysed and CRF-dialysed rats.
Results. The microscopic evaluation of the testicular structure showed that CRF did not affect testicular 
histology. Immunohistochemical evaluation showed that VEGF was expressed in the cytoplasm of primary 
and secondary spermatocyte series as well as the early spermatids. Staining intensity was lower in sperma-
tocytes going through the first meiotic division. TGF-a was expressed in the nuclei of spermatogonia and 
primary spermatocytes with stronger staining intensity in spermatogonia. The intensity of VEGF staining 
was similar in control and experimental animals, however, TGF-a expression was lower in the CRF group. 
Conclusions. The continuous expression of VEGF in spermatocytes and spermatids suggests that the applied 
model of CRF does not directly disrupt morphology of seminiferous epithelium, thus also spermiogenesis. 
However, difference between control rats and CRF group in TGF-a immunopositivity, which was localised in 
spermatogonial mitosis step, may suggest the interference of CRF with early stages of spermatogenesis. (Folia 
Histochemica et Cytobiologica 2014, Vol. 52, No. 4, 308–316)
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Introduction
Hypothalamic-pituitary-gonadal axis is important in 
the regulation of testis function; however, receptors 
for the pituitary-derived gonadotropins are expressed 
exclusively on somatic cells [1]. The hormonal regu-
lation of testis growth is mediated by paracrine and 
autocrine effects of different growth factors [2]. There-
fore, locally secreted regulatory factors are necessary 
to modulate cell functions in spermatogenesis [3] 
and steroidogenesis [4]. Male gonad is regulated by 
growth factors both inducing specific differentiation 
steps, and acting primarily as environmental or sur-
vival factors in genetically predetermined steps [5, 6].
Leydig cells and possibly also other testicular cells se-
crete vascular endothelial cell growth factor (VEGF), 
whereas the receptors, VEGF-R1 and VEGF-R2, are 
expressed on testicular blood vessels [7–9]. VEGF is 
one of the most potent angiogenic and permeabili-
309VEGF and TGF-a expression in rat testis during chronic renal failure
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.a2014.0032
www.fhc.viamedica.pl
ty-increasing factors [10]. VEGF may be involved in 
mediating testicular growth and regression in season-
ally breeding animals [11].
Transforming growth factor-alpha (TGF-a) and epi - 
dermal growth factor (EGF) bind to a common mem-
brane receptor (EGFR) and exert identical biological 
effects on proliferation, differentiation and differen-
tiated functions in a wide variety of target cells [12– 
–15]. In the postnatal testis, TGF-a and EGFR were 
found to stimulate proliferation, differentiation, 
and migration of Sertoli, Leydig, and peritubular 
cells [16, 17].
At the onset of puberty (around days 10–15 in the 
rat), Sertoli cells cease to divide and become postmi-
totic [18]. Sertoli cells play a key role in the initiation 
of spermatogenesis. Sertoli-Sertoli and Sertoli-germ 
cell interface form the blood-testis barrier (BTB) and 
organizes the seminiferous epithelium into a basal 
epithelial and an adluminal (apical) compartment to 
accommodate the rapid changes in germ cell morpholo-
gy during spermatogenesis, in particular spermiogene-
sis, as well as germ cell transport across the BTB [19]. 
Spermatocytes and spermatids are not motile cells 
per se, instead cytoskeletal F-actin organization in 
the mammalian testis which is maintained via the 
combined action of epidermal growth factor receptor 
pathway substrate 8 (Eps8, an actin filament barbed 
end capping and bundling protein) [20, 21], palladin 
(an actin cross-linking and bundling protein) [22] and 
espin [23] which help in the transporting of developing 
spermatids across the seminiferous epithelium.
Foetal Leydig cells originate by differentiation 
from mesenchyme-like precursors and once differen-
tiated, no longer divide under normal conditions [18]. 
Leydig cells differentiate and secrete testosterone 
during early foetal life which is required for embryonic 
development and sexual maturation. Observations 
suggest that all the testis cell populations provide 
potential targets for locally produced growth factors 
(e.g. TGF-a). [24] or neurotropin receptors such as 
low affinity neurotropin receptor (p75/LNGFR) [25]. 
However, besides the general knowledge that growth 
factors participate in different cellular compartments 
of the testis, little is known about the codistribution 
of TGF-a and VEGF in seminiferous tubuli.
In chronic stresses, testicular dysfunction is due to 
primary testicular failure with reduced production of 
testosterone and semen and elevated gonadotropin 
levels [26]. Chronic renal failure (CRF) is associated 
with impaired spermatogenesis and testicular damage, 
often leading to infertility. A decreased volume of 
ejaculate combined with low or complete azoosper-
mia and a low percentage of motility has been shown 
in semen analysis [27]. Leydig and Sertoli cells are 
prone to defects in their hormonal regulation. This 
latter effect might occur with either gonadotropin 
deficiency or resistance, rather than being a cytotoxic 
effect of uraemia when spermatogonia would be most 
affected [28]. The disorders of the pituitary-gonadal 
axis rarely normalize with initiation of haemodialysis 
or peritoneal dialysis and, in fact, often progress [29].
Although stimulatory or inhibitory effects of 
VEGF and TGF-a on different compartments of 
testis have been demonstrated, to our best knowled-
ge, no data describe the simultaneous expression of 
these growth factors in CRF. We hypothesize that 
VEGF and TGF-a would have spatially and tempo-
rally specific roles in rat testis under CRF conditions. 
Therefore, we decided to investigate the expression 
and localization of VEGF and TGF-a in rat testicular 
tissue in an experimental model of CRF.
Material and methods
Animals, surgical technique and peritoneal dialysis. The 
study was carried out on 24 adult male Wistar rats, aged 
between 10 and 12 weeks, weighing 200–330 g. Akdeniz 
University Animal Ethics Committee approved the research 
protocol. CRF was induced by partial nephrectomy under 
general anaesthesia with pentobarbital 50 mg/kg (i.p.). The 
left kidney was exposed through a flank incision, and both 
the upper and lower poles and approximately one third of 
the remaining cortical tissue of that kidney was excised with 
the help of bipolar cauterization. During the same session, 
after mobilizing the adrenal gland, the right kidney was 
removed after ligation of the renal artery, vein, and ureter. 
This procedure resulted in a resection of more than 85% of 
the renal tissue as previously described [30].
Four weeks later, a silicon catheter (Kawasumi venous 
fistula set, 16-gauge, 35-mm, Lot No. 9718A7) was intro-
duced into the abdominal cavity modifying the protocol 
described by Miller et al. [31]. The catheter length was de-
termined for each animal, and wedge-shaped smooth holes 
were made using a sterile surgical blade 3–4 cm from the 
distal end of the catheter. The catheter was pushed over a 
trocar, creating a subcutaneous track ending at the back of 
the animal’s neck. The catheter was closed by a Luer-Lock 
adaptor. Each morning, under sterile conditions, a catheter 
was passed through the permanent indwelling catheter, and 
the peritoneal cavity was rinsed with 20 mL pre-warmed 
saline. Afterwards, ceftazidime (125 mg/L) and gentamicin 
(8 mg/L) were given intraperitoneally. This procedure 
was continued until the beginning of chronic peritoneal 
dialysis (PD) [30]. Each morning, the Luer-Lock adaptor 
was removed and a sterile catheter was passed through the 
permanent indwelling catheter and rinsed with 20 mL pre-
warmed saline. Five minutes later, this fluid was drained 
and 20 mL dialysis fluid, containing either 1.36 or 3.86% 
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glucose, was given infused intraperitoneally for 4 h in the 
anaesthetized animal.
After the first dwell time of 4 h, the dialysis fluid was 
drained as much as possible, the peritoneum was rinsed with 
20 mL pre-warmed saline, and the Luer-Lock adaptor was 
closed. Each evening, after removing the adaptor and rinsing 
with 20 mL pre-warmed saline, 20 mL icodextrin was given 
for 10 h, and then it was drained as completely as possible, 
and the peritoneum was rinsed with pre-warmed saline. 
Ceftazidime (125 mg/L) and gentamicin (8 mg/L) were 
added to every dialysate exchange. The dialysis procedure 
was performed for 8 weeks.
Before chronic PD begun, the rats were divided into 
three groups. The first group consisted of 6 normal rats and 
served as the control group (group 1). In 8 rats, CRF was 
induced and the catheter was implanted, but the dialysis 
procedure was not performed until the end of the study 
(group 2). In 10 rats with CRF, chronic PD was performed 
by dialysis fluids containing 1.36% glucose and icodextrin 
(group 3). Each animal was housed in a metabolic cage 
and the daily fluid and food intake, 24-hour urine volume, 
and body weight were followed for the entire duration of 
the experiment. On Tuesdays of each week, blood sam-
ples were taken by puncture of the tail vein to measure 
creatinine and urea concentrations. Creatinine clearance 
was monitored every 2 weeks throughout the study period. 
Creatinine clearance (CCr) is calculated from the creatini-
ne concentration in the collected urine sample (a 24-hour 
urine collection) (UCr), urine volume (24-hour volume), 
and the plasma concentration (PCr) (CCr = UCr × 24 
hour volume/PCr × 24 × 60 min). Animals with normal 
serum creatinine levels before the start of PD were con-
sidered as failures.
We chose to evaluate the animals at 16 weeks postope-
ratively, because this time point permitted the evaluation of 
a cohort of animals in which uraemia had been produced in 
a stable homeostatic state.
Tissue collection. At the end of the PD procedure, both 
testes were delivered into the abdomen and bilateral orchiec-
tomy was performed. The animals were then sacrificed using 
a lethal overdose of anaesthesia. The testicular samples were 
fixed by immersion in Bouin’s fixative (75 mL of saturated 
aqueous solution of picric acid; Sigma-Aldrich, Steinheim, 
Germany), 25 mL of formalin (Merck, Whitehouse Station, 
NJ, USA) and 5 mL of glacial acetic acid (Sigma-Aldrich) 
and routinely processed for paraffin embedding.
Immunohistochemistry. For immunohistochemical analysis, 
5- to 6-µm-thick tissue sections were mounted on poly-L-ly-
sine-coated slides. After deparaffinization, slides were boiled 
in citrate buffer (pH 6.0) for 10 min for antigen retrieval 
and cooled for 20 min at room temperature. The following 
single and sequential immunoenzymatic double staining 
methods were performed according to Petraki et al. [32] 
and the manufacturer’s instructions.
VEGF. After washes in phosphate-buffered saline (PBS), an 
endogenous alkaline phosphatase (AP) inhibiting reagent, 
containing 0.0002 mol/L levamisole (Dako X3021, Dako, Glo-
strup, Denmark) was applied for 10 min at room temperature. 
The primary antibody, mouse anti-human VEGF (sc-7269, 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was 
incubated overnight at 4°C. After several washes in PBS, the 
antibody was detected with alkaline phosphatase (LabVision, 
Fremont, CA, USA) detection system and visualized with Fast 
Red as substrate (Dako). The sections were counterstained 
with Mayer’s haematoxylin (Dako), mounted with Kaiser’s 
gelatine (Merck) without any further dehydration.
TGF-a. After PBS washes, the endogenous peroxidase acti-
vity was inhibited by incubation in methanol containing 3% 
H2O2 for 10 min. After several washes in PBS, the sections 
were blocked with a universal blocking serum (LabVision) 
for 7 min at room temperature in a humidified chamber. Ex-
cess serum was drained and mouse monoclonal TGF-a pri-
mary antibody (GF10; Calbiochem, Cambridge MA, USA) 
was applied as 2 µg/mL for 1 h at room temperature. After 
several washes in PBS, the antibody was detected with an 
avidin-biotin, horse-radish peroxidase complex (LabVision). 
The sections were rinsed with PBS and antibody complexes 
were visualized by incubation with 5,5’-diaminobenzidine 
tetrahydrochloride (DAB) chromogen (BioGenex, Fremont, 
CA, USA). Sections were not counterstained to prevent ma-
sking of the nuclear immunolabelling, dehydrated, mounted 
with Entellan (Merck), and visualized by light microscopy.
Double labelling. A sequential immunoenzymatic double 
staining method was also performed, in order to compare 
the localization of the two studied antigens. The tissue 
sections were incubated using the first primary antibody 
(TGF-a), and detected with avidin-biotin, horse-radish 
peroxidase complex (LabVision) as described above; then 
rinsed in distilled water and sequentially incubated with 
the second primary antibody (VEGF) and detected with 
alkaline phosphatase (LabVision) system. The sections were 
not counterstained, mounted with Kaiser’s gelatine (Merck) 
without any further dehydration.
Tissues from control and experimental groups were proces-
sed at the same time. For controls, sections were treated 
with appropriate mouse IgG and diluted to the same final 
protein concentration as the primary antibody. Immunohi-
stochemical staining was evaluated in seminiferous tubules 
in a blinded fashion to the groups of the tissues by 2 inde-
pendent observers (GA, YSC) and expressed as the intensity 
of positively stained cells. Briefly, for each slide, 10 different 
areas were evaluated using the light microscope (Zeiss 
Axioplan, Oberkochen, Germany) at 200 × magnification, 
and the intensity of VEGF and TGF-a immunolabellings 
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was expressed semiquantitatively as negative (–), weak (+), 
moderate (++) or strong (+++).
Periodic acid-Schiff (PAS) staining. In order to identify 
glycoproteins within the acrosome of spermatids, we perfor-
med PAS staining. Routinely deparaffinized and rehydrated 
sections were oxidized in 0.5% periodic acid solution for 5 
min and rinsed in distilled water. Then, the sections were 
placed in Schiff’s reagent for 15 min and washed in tap wa-
ter for 5 min. Finally, they were counterstained in Mayer’s 
haematoxylin for 1 min, washed in tap water, dehydrated, 
cleared and mounted.
Statistical analysis. Statistical evaluations were performed 
using SPSS (Statistical Package for Social Sciences) for 
Windows 13.0 software (SPSS Inc., Chicago, IL, USA). 
Normality was tested by Shapiro-Wilk test. The Student’s t 
test was used to compare the body weights, serum creatinine 
and urea concentrations, and creatinine clearances between 
the CRF groups and the control group. A p value of < 0.05 
was considered statistically significant.
Results
Induction of chronic renal failure
Of the 24 rats in this study, six died (two and four in gro-
ups 2 and 3, respectively) because of peritoneal trau-
ma, peritonitis attacks, and other problems. A signi - 
ficant decrease in the creatinine clearance value 
was measured in the CRF groups (groups 2 and 
3; n = 12, mean 0.43 ± 0.11 mL/min) compared 
with control group (group 1; n = 6; 2.88 mL/min, 
p< 0.05). The mean creatinine clearance value in the 
CRF group represented 14.8% of normal, thus we 
could easily conclude that end-stage renal failure was 
successfully induced in these rats. All CRF animals 
had low creatinine clearance values. Although the 
body weight initially increased (by 10%) in the CRF 
group during the first week after surgery, before PD 
began, there was eventually a body weight loss (by 
15%) in the same group. However, before start of PD, 
no statistically significant difference was found in the 
body weight of the CRF (groups 2, 3) and non-CRF 
(group 1) animals.
Microscopic evaluation of VEGF presence  
in rat testis of control and CRF groups
Immunohistochemical analysis showed that VEGF 
was expressed in the cytoplasm of spermatocyte se-
ries that were most likely pachytene spermatocytes 
as well as early spermatids forming up the adlumi-
nal compartment of the testis (Figure 1). The cells 
which morphologically appeared to be preleptotene 
Figure 1. Immunohistochemical localization of VEGF in rat testis. Control (A), CRF (B) and CRF+PD (C) groups. 
Representative negative control section (D). Abbreviations as for Table 1. Pachytene spermatocytes and round spermatid 
cytoplasms stained positively for VEGF in the three rat groups. Blue arrow: elongated spermatid; green arrow: round 
spermatid; black arrow: pachytene spermatocyte; yellow arrow: preleptotene spermatocyte; red arrow: spermatogonium; 
pink arrow: Sertoli cell; black arrowhead: Leydig cell. Chromogen: Fast Red. Counter stain: Mayer’s haematoxylin.  
Original magnification × 40
A B
DC
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spermatocytes residing in the basal compartment of 
the seminiferous tubules were negative for VEGF 
immunostaining. Staining intensity exhibited varia-
tions among spermatocytes which were probably 
committed to form round spermatocytes (Figure 1). 
VEGF immunoreactivity was not observed in mature 
spermatozoa. Also VEGF staining intensities in the 
seminiferous tubules and testicular cells were similar 
in control (Figure 1a), CRF (Figure 1b) and CRF+PD 
(Figure 1c) groups, which is outlined in Table 1. 
Leydig cells and Sertoli cells were negative for 
VEGF in all studied groups (Table 1).
Microscopic evaluation of TGF-a presence  
in rat testis of control and CRF-animals 
TGF-a was expressed in the nuclei of basal cells which 
were presumably spermatogonia and preleptotene 
spermatocytes (Figure 2a). TGF-a immunoreactivity 
was present in perinuclear proacrosomal granules in 
the round spermatids (Figure 2a). We also observed 
periodic acid-Schiff (PAS) staining, in parallel with 
immunohistochemistry, to mark the acrosome by a 
conventional method. Serial cross sections of testis 
were used for TGF-a labelling and PAS staining. PAS 
staining was observed in proacrosomal granules that 
have coalesced and formed one big granule as well 
as in basement membrane of tubuli and spermatozoa 
heads (Figure 2a, insert). Mature spermatozoa were 
immunonegative for TGF-a. When compared with the 
control group, TGF-a staining intensity was lower in 
the CRF (Figure 2b) and CRF+PD groups (Figure 2c, 
Table 1). 
Leydig cells stained positively for TGF-a in all 
animal groups, however, Sertoli cells were immuno-
negative (Table 1).
Double immunohistochemical staining 
Double immunohistochemical labelling of the control, 
CRF and CRF+PD groups evidently showed that 
VEGF immunopositive spermatogenic cells compri-
sed the adluminal compartment and TGF-a immu-
nopositive cells comprised the basal compartment of 
the seminiferous tubule (Figure 3). The adluminal 
compartment specific VEGF immunolabelling and 
basal compartment specific TGF-a immunostaining 
did not overlap in control, CRF and CRF + PD testes 
sections (Figure 3a–c).
Discussion
In the present study, we examined the immunolocali-
zation of VEGF and TGF-a in a rat CRF model. Our 
results demonstrate that the testis histology was not 
directly affected by CRF. The expression of VEGF 
in pachytene spermatocyte and spermatids suggests 
that CRF may not affect late spermatocyte stages. 
However, decreased TGF-a expression in spermato-
gonia and preleptotene spermatocytes suggests that 
CRF probably exerts an inhibitive effect on sperma-
togonia. Since we observed no co-localization of the 
two growth factors when a single immunochemistry 
was performed, we ascertained this observation by 
applying a double labelling approach which clearly 
identified the VEGF and TGF-a immunopositivities 
in the adluminal compartment and the basal compart-
ment, respectively.
Interestingly, there was an exception for TGF-a 
immunolocalization in the acrosomal vesicles of 
developing pachytene and round spermatids. In rats, 
classification of the seminiferous epithelium cycle by 
Leblond and Clermont [33] defines 14 stages (desig-
Table 1. Localization of VEGF and TGF-a in control, chronic renal failure (CRF) and CRF + peritoneal dialysis  
(CRF+PD) groups
Cell type Control CRF CRF+PD
VEGF TGF-a VEGF TGF-a VEGF TGF-a
Elongated spermatid – – – – – –
Round spermatid + – + – + –
Pachytene spermatocyte +++ – ++ – ++ –
Preleptotene spermatocyte – +++ – + – ++
Spermatogonium – ++ – + – +
Sertoli – – – – – –
Leydig – + – + – +
Immunohistochemical detection of VEGF and TGF-a was performed as described in Methods. The intensity of immunoreactivity was assessed as 
negative (–), weak (+), moderate (++), and strong (+++)
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Figure 2. Immunohistochemical localization of TGF-a in rat testis. Control (A), CRF (B) and CRF+PD (C) groups. 
Representative negative control section (D). Periodic acid Schiff (PAS) staining (insert in Fig. 2a). Abbreviations as for 
Table 1. Preleptotene spermatocytes and spermatogonium nuclei as well as the Leydig cells showed TGF-a immunoreac-
tivity. TGF-a staining was weak in the CRF group. Turquoise arrowhead: acrosomal vesicles; yellow arrow: preleptotene 
spermatocyte; red arrow: spermatogonium; black arrowhead: Leydig cell. Chromogen: DAB. Counter stain: not applied. 
Original magnification × 40 (A–D), × 100 (insert)
Figure 3. Representative double immunohistochemical labelling of rat testis for VEGF and TGF-a. Control (A), CRF (B) 
and CRF+PD (C) groups. Representative negative control section (D). Abbreviations as for Table 1. VEGF and TGF-a 
immunohistochemical labellings were visualized using the chromogens, Fast Red (red) and DAB (brown) respectively. 
Counter stain: not applied. Original magnification × 40
A B
DC
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nated I–XIV) in which spermiogenesis, which refers 
to the morphological transformation of spermatids 
into spermatozoa, involves 19 differentiation steps 
(from 1 to 19). Periodic Acid Schiff (PAS) reaction 
is an accepted conventional method of labelling the 
acrosome [34] and studying the seminiferous tubules 
histology [35]. The SP-10 protein, whose intra-acro-
somal localization was found in mammalian male 
germ cells [36], has been recently applied for staging 
the mouse seminiferous cycle [37]. According to our 
findings, TGF-a is similarly present in proacrosomal 
granules of rat spermatids suggesting the role of 
TGF-a in normal spermatid development. The further 
differentiated forms of spermatids and spermatozoa 
were not labelled which may suggest posttranslational 
modifications of TGF-a during acrosome formation.
Spermatogenesis can be broadly divided into sever-
al discrete events: (1) renewal of spermatogonial stem 
cells and spermatogonia via mitosis, (2) proliferation 
(via mitosis) and differentiation of spermatogonia 
through type A and type B, and eventually prelepto-
tene spermatocytes, (3) meiosis, (4) spermiogenesis 
(transformation of round spermatids to elongated 
spermatids and spermatozoa) and (5) spermiation 
(the release of sperm from the epithelium into the 
tubule lumen) [38]. Spermatogenesis and steroi-
dogenesis can be affected by chronic renal failure 
causing deterioration of testicular function [39]. Renal 
failure is associated with the retention of a variety 
of toxic compounds responsible for the uremic syn-
drome. One of the most encountered complications 
is CRF-associated testicular dysfunction, which often 
causes infertility [40]. The exact pathophysiological 
mechanism involved in CRF-induced testicular dam-
age is not fully understood. Haemodialysis patients 
have reduced testicular volume, indicating impaired 
spermatogenesis [41], however, recovery of hormonal 
and spermatogenic abnormalities occur after renal 
transplantation [27, 39]. Spermatozoa obtained from 
uremic patients show improved ultrastructural fea-
tures after renal transplantation, and a low dose of 
immunosuppressant is suggested to prevent degener-
ating effects of immunosuppressive therapy on semi-
niferous epithelia [42]. However, Adachi et al. applied 
a stepwise-nephrectomy procedure and demonstrated 
that testicular histology has not been affected by CRF 
in rats [43]. This observation is compatible with our 
previous results that the testicular histology between 
the CRF and control groups was not statistically dif-
ferent based on the Johnsen’s scores [30].
Several studies have found that VEGF is involved 
in both neonatal [44] and postnatal [45] rodent tes-
tis development. It was demonstrated that altering 
VEGFA isoform activity in the testis in vivo resulted 
in significant changes in the ability of spermatogonial 
stem cells to self-renew and colonize seminiferous 
tubules [44]. Recently, in a mouse VEGFA knockout 
model it has been observed that although testis weight 
did not change, the seminiferous epithelium was 
disorganized which suggested that VEGFA isoforms 
secreted by Sertoli cells and germ cells are necessary 
for the maintenance of undifferentiated spermatogo-
nia, sperm numbers and normal male fertility [46].
Locally produced testicular factors are of potential 
physiological significance [47]. Epidermal growth 
factor (EGF)/TGF-a is a family of growth factors that 
has attracted attention as putative regulators of em-
bryonic [48] and testicular [24] development. Earlier 
results [49] supported by more recent findings [50] 
indicate that EGF/TGF-a family members are also 
directly involved in the regulation of spermatogenesis.
It was reported that CRF models based on 75% 
surgical nephron reduction resulted in FVB/N mice 
strain with severe tubulo-interstitial kidney lesions, 
whereas C57BL6xB6D2F1 strain is resistant to early 
renal deterioration [51]. Additionally, it was shown 
that TGF-a expression markedly increased after 
nephron reduction exclusively in FVB/N mice, and 
this increase preceded the development of renal le-
sions [52]. Furthermore, pharmacologic inhibition of 
the EGFR prevented the development of renal lesions 
in the sensitive FVB/N strain [52]. These data suggest 
that variable TGF-a expression may explain, in part, 
the genetic susceptibility to the progression of chronic 
kidney disease (CKD). Thus, EGFR inhibition may 
be a therapeutic strategy to counteract the genetic 
predisposition to CKD. Similarly, administration of 
VEGF was found to be effective in reducing long-
term histologic damage resulting from testicular 
ischemia-reperfusion, and preservation of histologic 
parameters, such as mean seminiferous tubular diam-
eter and germinal epithelial cell thickness [53].
Growth factors are considered to participate in 
creating a suitable niche for spermatogenesis [50]. 
Mammalian testis is a self-renewing cell system in 
which proliferation and differentiation of stem cells, 
i.e. spermatogonia, takes place in microenvironments 
that are described as niche. Rat spermatogonia are 
preferentially located near the interstitial regions [54]. 
These regions were considered as spermatogonial 
niches where Leydig cells, macrophages, and lym-
phatic and blood vessels are commonly found in 
topographically critical locations. Similarly in human 
testes, peritubular wall cells contribute to the sper-
matogonial stem cell (SSC) niche which is supported 
by the production of glial cell line-derived neurotroph-
ic factor (GDNF), and its receptor GDNF family re-
ceptor alpha-1 (GFRa1), responsible for maintaining 
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SSCs [55]. Specific factors emanated by those niches 
such as epidermal growth factor (EGF)-like growth 
factors, heparin binding (HB)–EGF, amphiregu-
lin, and TGF-a are considered to support human 
spermato genesis [50]. Our results supported the 
hypothesis that VEGF and TGF-a have cell-specific 
expressions through the seminiferous epithelia and 
chronic renal failure neither affects these localizations 
nor deteriorates testicular histology. In our study the 
continuous expression of VEGF in pachytene sper-
matocytes and spermatids not only in normal but also 
in CRF rats suggests that chronic kidney disease may 
not affect spermiogenesis. However, TGF-a might be 
important in spermatogonial mitosis step and CRF 
might have temporary influence on spermatogonia 
causing the impairment in the spermatogonial phase, 
during which stem cells divide to replace themselves 
and provide a population of committed spermatogo-
nia. These spatial and temporal expressions of VEGF 
and TGF-a remain to be elucidated in further re-
search and clinical conditions.
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